Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.

CNS Drugs

Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA, 94305-5717, USA,

Published: June 2015

Pharmacologic treatments targeting specific molecular mechanisms relevant for autism spectrum disorder (ASD) are beginning to emerge in early drug development. This article reviews the evidence for the disruption of glutamatergic neurotransmission in animal models of social deficits and summarizes key pre-clinical and clinical efforts in developing pharmacologic interventions based on modulation of glutamatergic systems in individuals with ASD. Understanding the pathobiology of the glutamatergic system has led to the development of new investigational treatments for individuals with ASD. Specific examples of medications that modulate the glutamatergic system in pre-clinical and clinical studies are described. Finally, we discuss the limitations of current strategies and future opportunities in developing medications targeting the glutamatergic system for treating individuals with ASD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515163PMC
http://dx.doi.org/10.1007/s40263-015-0252-0DOI Listing

Publication Analysis

Top Keywords

individuals asd
12
glutamatergic system
12
developing medications
8
medications targeting
8
targeting glutamatergic
8
pre-clinical clinical
8
glutamatergic
6
glutamatergic dysfunction
4
dysfunction autism
4
autism progress
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!